On September 22, Dr. Antonio Pinto of the National Cancer Institute in Naples, Italy announced that two doses of Aloxi (palonosetron) are more effective than one at preventing chemotherapy-induced nausea. He presented his results at the European Cancer Organization and European Society for Medical Oncology’s joint conference in Berlin.

Dr. Pinto studied 60 cancer patients, including some with multiple myeloma, who were being treated with chemotherapy. All patients received one dose of Aloxi, approved by the Food and Drug Administration in July 2003, and dexamethasone (Decadron), another anti-nausea medication, 30 minutes …